City of Hope researchers found kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug, Fotivda (tivozanib), compared to an alternative approved by FDA.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
